Langer Daniel A, Das Amitava, Semela David, Kang-Decker Ningling, Hendrickson Helen, Bronk Steven F, Katusic Zvonimir S, Gores Gregory J, Shah Vijay H
Gastrointestinal Research Unit and Fiterman Center for Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Hepatology. 2008 Jun;47(6):1983-93. doi: 10.1002/hep.22285.
Hepatic stellate cells (HSCs) contribute to portal hypertension through multiple mechanisms that include collagen deposition, vasoconstriction, and regulation of sinusoidal structure. Under normal physiologic conditions, endothelial nitric oxide (NO) synthase-derived NO exerts paracrine effects on HSCs; however, in cirrhosis, NO generation is impaired in association with concomitant HSC activation and changes in sinusoidal structure, events that contribute significantly to the development of portal hypertension. These concepts, in combination with recent evidence that induction of HSC-selective apoptosis may represent a useful target for treatment of chronic liver disease, led us to examine if NO may further limit HSC function through apoptosis. Indeed, both NO donors and endothelial NO synthase overexpression promoted HSC apoptotic pathways. HSC death conferred by NO occurred through mitochondrial membrane depolarization and through a caspase-independent pathway. Furthermore, NO-induced apoptosis of HSC did not occur through the canonical pathways of soluble guanylate cyclase or protein nitration, but rather through the generation of superoxide and hydroxyl radical intermediates. Lastly, HSC isolated from rats after bile duct ligation were more susceptible to NO-induced apoptosis. These data indicate that NO promotes HSC apoptosis through a signaling mechanism that involves mitochondria, is mediated by reactive oxygen species, and occurs independent of caspase activation.
We postulate that NO-dependent apoptosis of HSCs may maintain sinusoidal homeostasis, and may represent an additional beneficial effect of NO donors for therapy of portal hypertension.
肝星状细胞(HSCs)通过多种机制导致门静脉高压,这些机制包括胶原蛋白沉积、血管收缩和窦状结构调节。在正常生理条件下,内皮型一氧化氮(NO)合酶衍生的NO对HSCs发挥旁分泌作用;然而,在肝硬化中,随着HSC激活和窦状结构改变,NO生成受损,这些事件对门静脉高压的发展有显著影响。这些概念,结合最近的证据表明诱导HSC选择性凋亡可能是治疗慢性肝病的一个有用靶点,促使我们研究NO是否可能通过凋亡进一步限制HSC功能。事实上,NO供体和内皮型NO合酶过表达均促进HSC凋亡途径。NO导致的HSC死亡通过线粒体膜去极化和非半胱天冬酶依赖性途径发生。此外,NO诱导的HSC凋亡不是通过可溶性鸟苷酸环化酶或蛋白质硝化的经典途径发生,而是通过超氧化物和羟基自由基中间体的产生发生。最后,从胆管结扎后的大鼠分离的HSC对NO诱导的凋亡更敏感。这些数据表明,NO通过一种涉及线粒体、由活性氧介导且独立于半胱天冬酶激活的信号机制促进HSC凋亡。
我们推测,HSCs的NO依赖性凋亡可能维持窦状稳态,并且可能代表NO供体治疗门静脉高压的另一种有益作用。